Iopamidol

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C17H22I3N3O8
Molecular Weight	777.0853
Optical Activity	( - )
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C[C@H](O)C(=O)NC1=C(I)C(C(=O)NC(CO)CO)=C(I)C(C(=O)NC(CO)CO)=C1I

InChI

InChIKey=XQZXYNRDCRIARQ-LURJTMIESA-N

InChI=1S/C17H22I3N3O8/c1-6(28)15(29)23-14-12(19)9(16(30)21-7(2-24)3-25)11(18)10(13(14)20)17(31)22-8(4-26)5-27/h6-8,24-28H,2-5H2,1H3,(H,21,30)(H,22,31)(H,23,29)/t6-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C17H22I3N3O8
Molecular Weight	777.0853
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/018735s056,020327s010lbl.pdf
Curator's Comment: description was created based on several sources, including: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ae8c18c9-3e7d-4515-b980-120025a88fc1 http://www.rxlist.com/isovue-drug.htm

Iopamidol is a nonionic, low-osmolar iodinated contrast agent. Iopamidol is indicated for angiography, pediatric angiocardiography, selective visceral arteriography and aortography, peripheral venography, and adult and pediatric intravenous excretory urography and intravenous adult and pediatric contrast enhancement of computed tomographic. Renal toxicity has been reported in a few patients with liver dysfunction who were given oral cholecystographic agents followed by intravascular contrast agents. Intravascular injection of contrast media is frequently associated with the sensation of warmth and pain especially in peripheral arteriography and venography. In angiocardiography the adverse reactions are: hot flashes, angina pectoris, flushing, bradycardia, hypotension, hives.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
vessels and anatomical structures 3 Target ID: vessels and anatomical structures Sources: http://cursoenarm.net/UPTODATE/contents/mobipreview.htm?37/56/38797?source=see_link#F7914497	Activator 1447

Conditions

Condition	Modality	Highest Phase	Product
Cardiovascular diseases 72 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/018735s056,020327s010lbl.pdf	Diagnostic	Approved 8583	ISOVUE-M 300 Approved Use ISOVUE-M (lopamidol Injection) is indicated for intrathecal administration in adult neuroradiology including myelography (lumbar, thoracic, cervical, total columnar), and for contrast enhancement of computed tomographic (CECT) cisternography and ventriculography. ISOVUE-M 200 (lopamidol Injection) is indicated for thoraco-lumbar myelography in children over the age of two years. Launch Date 1985
Urinary system disease 13 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/018735s056,020327s010lbl.pdf	Diagnostic	Approved 8583	ISOVUE-M 300 Approved Use ISOVUE-M (lopamidol Injection) is indicated for intrathecal administration in adult neuroradiology including myelography (lumbar, thoracic, cervical, total columnar), and for contrast enhancement of computed tomographic (CECT) cisternography and ventriculography. ISOVUE-M 200 (lopamidol Injection) is indicated for thoraco-lumbar myelography in children over the age of two years. Launch Date 1985
Glioma 25 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/018735s056,020327s010lbl.pdf	Diagnostic	Approved 8583	ISOVUE-M 300 Approved Use ISOVUE-M (lopamidol Injection) is indicated for intrathecal administration in adult neuroradiology including myelography (lumbar, thoracic, cervical, total columnar), and for contrast enhancement of computed tomographic (CECT) cisternography and ventriculography. ISOVUE-M 200 (lopamidol Injection) is indicated for thoraco-lumbar myelography in children over the age of two years. Launch Date 1985

C_max

Value	Dose	Co-administered	Analyte	Population
112.7 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3096110	15 mL single, intrathecal dose: 15 mL route of administration: Intrathecal experiment type: SINGLE co-administered:		IOPAMIDOL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
931 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3096110	15 mL single, intrathecal dose: 15 mL route of administration: Intrathecal experiment type: SINGLE co-administered:		IOPAMIDOL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
2 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/018735s054lbl.pdf	single, intravenous		IOPAMIDOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
100% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9084958			IOPAMIDOL plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
61 % single, intravenous Dose: 61 % Route: intravenous Route: single Dose: 61 % Sources: https://pubmed.ncbi.nlm.nih.gov/28483940/	unhealthy, 21 years Health Status: unhealthy Age Group: 21 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/28483940/	Disc. AE: Hepatotoxicity... AEs leading to discontinuation/dose reduction: Hepatotoxicity (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/28483940/
612 mg/mL single, intrathecal Dose: 612 mg/mL Route: intrathecal Route: single Dose: 612 mg/mL Sources: https://pubmed.ncbi.nlm.nih.gov/16369390/	unknown, 45 years Health Status: unknown Age Group: 45 years Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/16369390/	Disc. AE: Generalized tonic-clonic seizure... AEs leading to discontinuation/dose reduction: Generalized tonic-clonic seizure (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/16369390/
54250 mg single, intravenous Dose: 54250 mg Route: intravenous Route: single Dose: 54250 mg Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/	unknown, adult and children Health Status: unknown Age Group: adult and children Sex: unknown Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/	Other AEs: Extravasation... Other AEs: Extravasation (18 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/
62775 mg single, intravenous Dose: 62775 mg Route: intravenous Route: single Dose: 62775 mg Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/	unknown, adult and children Health Status: unknown Age Group: adult and children Sex: unknown Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/	Other AEs: Extravasation... Other AEs: Extravasation (5 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/
68544 mg single, intravenous Dose: 68544 mg Route: intravenous Route: single Dose: 68544 mg Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/	unknown, adult and children Health Status: unknown Age Group: adult and children Sex: unknown Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/	Other AEs: Extravasation... Other AEs: Extravasation (23 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/
69768 mg single, intravenous Dose: 69768 mg Route: intravenous Route: single Dose: 69768 mg Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/	unknown, adult and children Health Status: unknown Age Group: adult and children Sex: unknown Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/	Other AEs: Extravasation... Other AEs: Extravasation (32 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/
83700 mg single, intravenous Dose: 83700 mg Route: intravenous Route: single Dose: 83700 mg Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/	unknown, adult and children Health Status: unknown Age Group: adult and children Sex: unknown Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/	Other AEs: Allergic reaction... Other AEs: Allergic reaction (3 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/
87516 mg single, intravenous Dose: 87516 mg Route: intravenous Route: single Dose: 87516 mg Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/	unknown, adult and children Health Status: unknown Age Group: adult and children Sex: unknown Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/	Other AEs: Allergic reaction... Other AEs: Allergic reaction (46 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/
88740 mg single, intravenous Dose: 88740 mg Route: intravenous Route: single Dose: 88740 mg Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/	unknown, adult and children Health Status: unknown Age Group: adult and children Sex: unknown Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/	Other AEs: Allergic reaction... Other AEs: Allergic reaction (42 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/
612 mg/mL single, intravenous Dose: 612 mg/mL Route: intravenous Route: single Dose: 612 mg/mL Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/	unknown, adult and children Health Status: unknown Age Group: adult and children Sex: unknown Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/	Other AEs: Adverse event... Other AEs: Adverse event (74 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/
612 mg/mL single, intravenous Dose: 612 mg/mL Route: intravenous Route: single Dose: 612 mg/mL Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/	unknown, adult and children Health Status: unknown Age Group: adult and children Sex: unknown Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/	Other AEs: Adverse event... Other AEs: Adverse event (69 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/
61225 mg/mL single, intravenous Dose: 61225 mg/mL Route: intravenous Route: single Dose: 61225 mg/mL Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/	unknown, adult and children Health Status: unknown Age Group: adult and children Sex: unknown Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/	Other AEs: Allergic reaction... Other AEs: Allergic reaction (8 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/
775 mg/mL single, intravenous Dose: 775 mg/mL Route: intravenous Route: single Dose: 775 mg/mL Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/	unknown, adult and children Health Status: unknown Age Group: adult and children Sex: unknown Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/	Other AEs: Adverse event... Other AEs: Adverse event (8 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/
775 mg/mL single, intravenous Dose: 775 mg/mL Route: intravenous Route: single Dose: 775 mg/mL Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/	unknown, adult and children Health Status: unknown Age Group: adult and children Sex: unknown Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/	Other AEs: Adverse event... Other AEs: Adverse event (26 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/

AEs

AE	Significance	Dose	Population
Hepatotoxicity	1 patient Disc. AE	61 % single, intravenous Dose: 61 % Route: intravenous Route: single Dose: 61 % Sources: https://pubmed.ncbi.nlm.nih.gov/28483940/	unhealthy, 21 years Health Status: unhealthy Age Group: 21 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/28483940/
Generalized tonic-clonic seizure	1 patient Disc. AE	612 mg/mL single, intrathecal Dose: 612 mg/mL Route: intrathecal Route: single Dose: 612 mg/mL Sources: https://pubmed.ncbi.nlm.nih.gov/16369390/	unknown, 45 years Health Status: unknown Age Group: 45 years Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/16369390/
Extravasation	18 patients	54250 mg single, intravenous Dose: 54250 mg Route: intravenous Route: single Dose: 54250 mg Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/	unknown, adult and children Health Status: unknown Age Group: adult and children Sex: unknown Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/
Extravasation	5 patients	62775 mg single, intravenous Dose: 62775 mg Route: intravenous Route: single Dose: 62775 mg Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/	unknown, adult and children Health Status: unknown Age Group: adult and children Sex: unknown Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/
Extravasation	23 patients	68544 mg single, intravenous Dose: 68544 mg Route: intravenous Route: single Dose: 68544 mg Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/	unknown, adult and children Health Status: unknown Age Group: adult and children Sex: unknown Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/
Extravasation	32 patients	69768 mg single, intravenous Dose: 69768 mg Route: intravenous Route: single Dose: 69768 mg Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/	unknown, adult and children Health Status: unknown Age Group: adult and children Sex: unknown Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/
Allergic reaction	3 patients	83700 mg single, intravenous Dose: 83700 mg Route: intravenous Route: single Dose: 83700 mg Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/	unknown, adult and children Health Status: unknown Age Group: adult and children Sex: unknown Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/
Allergic reaction	46 patients	87516 mg single, intravenous Dose: 87516 mg Route: intravenous Route: single Dose: 87516 mg Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/	unknown, adult and children Health Status: unknown Age Group: adult and children Sex: unknown Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/
Allergic reaction	42 patients	88740 mg single, intravenous Dose: 88740 mg Route: intravenous Route: single Dose: 88740 mg Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/	unknown, adult and children Health Status: unknown Age Group: adult and children Sex: unknown Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/
Adverse event	74 patients	612 mg/mL single, intravenous Dose: 612 mg/mL Route: intravenous Route: single Dose: 612 mg/mL Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/	unknown, adult and children Health Status: unknown Age Group: adult and children Sex: unknown Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/
Adverse event	69 patients	612 mg/mL single, intravenous Dose: 612 mg/mL Route: intravenous Route: single Dose: 612 mg/mL Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/	unknown, adult and children Health Status: unknown Age Group: adult and children Sex: unknown Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/
Allergic reaction	8 patients	61225 mg/mL single, intravenous Dose: 61225 mg/mL Route: intravenous Route: single Dose: 61225 mg/mL Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/	unknown, adult and children Health Status: unknown Age Group: adult and children Sex: unknown Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/
Adverse event	8 patients	775 mg/mL single, intravenous Dose: 775 mg/mL Route: intravenous Route: single Dose: 775 mg/mL Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/	unknown, adult and children Health Status: unknown Age Group: adult and children Sex: unknown Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/
Adverse event	26 patients	775 mg/mL single, intravenous Dose: 775 mg/mL Route: intravenous Route: single Dose: 775 mg/mL Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/	unknown, adult and children Health Status: unknown Age Group: adult and children Sex: unknown Sources: https://pubmed.ncbi.nlm.nih.gov/22106356/

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:31711	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:31711
ChemicalBook	CB5384796	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB5384796
eMolecules	31588820	https://www.emolecules.com/cgi-bin/more?vid=31588820
eMolecules	36753566	https://www.emolecules.com/cgi-bin/more?vid=36753566
MolPort	MolPort-003-848-224	https://www.molport.com/shop/molecule-link/MolPort-003-848-224
ZINC	ZINC000003830947	http://zinc15.docking.org/substances/ZINC000003830947

PubMed

Title	Date	PubMed
CT arthrography of the glenohumeral joint: CT fluoroscopy versus conventional CT and fluoroscopy--comparison of image-guidance techniques.	2003-10	12944606
Assessment of small bowel Crohn disease: noninvasive peroral CT enterography compared with other imaging methods and endoscopy--feasibility study.	2003-10	12944602
Fate of pharmaceuticals--photodegradation by simulated solar UV-light.	2003-09	12871743
Effect of contrast injection protocol with dose tailored to patient weight and fixed injection duration on aortic and hepatic enhancement at multidetector-row helical CT.	2003-09	12736754
Assessment of pancreatic CT enhancement using a high concentration of contrast material.	2003-06-21	12816354
Nonionic contrast media are less nephrotoxic than ionic contrast media to rat renal cortical slices.	2003-06-05	12697376
[Successful use of transvenous angio-multidetector-CT in diagnosing cecal angiodysplasia as the cause of peranal hemorrhage].	2003-06	12811701
[Feasibility and optimization of the combined injection of contrast medium and normal saline with a single-syringe CT injection system].	2003-06	12811699
Three-dimensional CT angiography of the hepatic artery: use of multi-detector row helical CT and a contrast agent.	2003-06	12773687
Effectiveness of theophylline prophylaxis of renal impairment after coronary angiography in patients with chronic renal insufficiency.	2003-05-15	12745095
[Prospects of the use of non-ionic X-ray contrast media during endoscopic retrograde cholangiopancreatography].	2003-05-02	12722628
Simultaneous voiding cystourethrography and voiding urosonography.	2003-05	12751996
Intrathecal injection of contrast medium to prevent polymethylmethacrylate leakage during percutaneous vertebroplasty.	2003-05	12748112
Cartilage lesions in the ankle joint: comparison of MR arthrography and CT arthrography.	2003-05	12682790
Sonographic versus magnetic resonance arthrographic evaluation of full-thickness rotator cuff tears in millimeters.	2003-04-18	12700560
Effects of contrast media on erythrocyte aggregation during sedimentation.	2003-04	12769231
Ozonation: a tool for removal of pharmaceuticals, contrast media and musk fragrances from wastewater?	2003-04	12697241
Roles of intracellular Ca2+ and cyclic AMP in mast cell histamine release induced by radiographic contrast media.	2003-04	12690428
Comparison of carbon dioxide and iodinated contrast for cavography prior to inferior vena cava filter placement.	2003-04	12657391
Delayed side effects induced by iodinated contrast media, especially those associated with iodixanol.	2003-03	12659083
Early and late reactions following the use of iopamidol 340, iomeprol 350 and iodixanol 320 in cardiac catheterization.	2003-03	12612387
Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial.	2003-02-05	12578487
Interstitial CT lymphography-guided localization of breast sentinel lymph node: preliminary results.	2003-02	12605178
Nephrotoxicity of iopamidol in pediatric, adolescent, and young adult patients who have undergone allogeneic bone marrow transplantation.	2003-02	12563132
Visualization of breast lymphatic pathways with an indirect computed tomography lymphography using a nonionic monometric contrast medium iopamidol: preliminary results.	2003-02	12544070
Usefulness of electron beam tomography in the prone position for detecting atrial thrombi in chronic atrial fibrillation.	2003-01-25	12544247
Conditions of iodine contrast transfer from lumbosacral CSF to blood.	2003-01-15	12480090
Nonionic contrast neurotoxicity after coronary angiography mimicking subarachnoid hemorrhage.	2003	12736546
[CO2 angiography of transplanted kidneys].	2003	12650035
Administration of nonionic iodinated contrast medium does not influence the outcome of patients with ischemic brain infarction.	2003	12499710
Effective prophylactic protocol in delayed hypersensitivity to contrast media: report of a case involving lymphocyte transformation studies with different compounds.	2002-11	12409581
Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure.	2002-10-16	12392825
[A case of gastrectomy under continuous subdural anesthesia].	2002-10	12428324
A nonadhesive liquid embolic agent composed of ethylene vinyl alcohol copolymer and ethanol mixture for the treatment of cerebral arteriovenous malformations: experimental study.	2002-10	12405378
Experience of intravenous digital subtraction angiography (IV-DSA) in evaluation of neoadjuvant chemotherapy for advanced breast cancer.	2002-10	12402068
Role of contrast-enhanced dynamic CT in the diagnosis of active tuberculoma.	2002-10	12377853
Iodinated contrast medium-induced potassium release: the effect of mixing ratios.	2002-09-26	12296436
Aortic and hepatic enhancement and tumor-to-liver contrast: analysis of the effect of different concentrations of contrast material at multi-detector row helical CT.	2002-09	12202710
Enhanced radio sensitivity with iodinated contrast agents using monochromatic synchrotron X-rays on human cancerous cells.	2002-08	12188332
Optimization of contrast agent administration in MSCT angiography.	2002-08	12188276
Nonionic contrast media iohexol and iomeprol decrease renal arterial tone: comparative studies on human and porcine isolated vascular segments.	2002-08	12138360
Optimum iodine concentration of contrast material through microcatheters: hydrodynamic analysis of experimental results.	2002-07-21	12171337
[Method of injection of contrast medium for brain perfusion CT].	2002-07	12515965
Erythrodermic psoriasis precipitated by radiologic contrast media.	2002-06	12063501
Plasma endothelin, nitric oxide and atrial natriuretic peptide levels in humans after abdominal angiography.	2002-05	12100335
Mechanisms of blood pressure change after bolus injections of X-ray contrast media.	2002-05	12019900
The rabbit renal toxicity test: a sensitive in vivo test for the nephrotoxicity of contrast agents.	2002-05	12019897
Comparative tolerability of contrast media used for coronary interventions.	2002	12452733
[Effects of high iodine doses in parenteral roentgen contrast media administration on parameters of the pro-/antioxidant balance].	2002	12094394
[Iotrolan versus iopamidol. A controlled double-blind study with lumbar myelography].	1992-08	1410326

Patents

Sample Use Guides

In Vivo Use Guide

Peripheral Arteriograghy: For injection into the femoral artery or subclavian artery, 5 to 40 mL of ISOVUE-300 may be used; for injection into the aorta for a distal runoff, 25 to 50 mL may be used. Doses up to a total of 250 mL of ISOVUE-300 have been administered during peripheral arteriography.

Route of Administration: Intravascular

In Vitro Use Guide

Diffusion of iopamidol (300 and 200 mgI/ml) was studied in the cerebrospinal fluid (CSF). Test tubes containing CSF were kept in a waterbath at 37 degrees C. Contrast medium was injected along the wall into the tubes, and diffusion of contrast media in the tubes was followed with repeated computed tomography for 5 h. The contents of the tubes were then mixed by shaking, and the tubes were scanned immediately and 8 h later.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 17:34:41 GMT 2025` Edited by `admin` on `Mon Mar 31 17:34:41 GMT 2025`
Record UNII	JR13W81H44
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

Iopamidol

Official Name

English

Iopamiron

Preferred Name

English

Iopamidol [ORANGE BOOK]

Common Name

English

Iopamidol [EP monograph]

Common Name

English

Iopamidol [USAN]

Common Name

English

Iopamidol [VANDF]

Common Name

English

N1,N3-Bis[2-hydroxy-1-(hydroxymethyl)ethyl]-5-[[(2S)-2-hydroxy-1-oxopropyl]amino]-2,4,6-triiodo-1,3-benzenedicarboxamide

Systematic Name

English

SQ-13396

Code

English

(S)-N,N'-bis(2-Hydroxy-1-(hydroxymethyl)ethyl)-2,4,6-triiodo-5-lactamidoisophthalamide

Systematic Name

English

Iopamidol [USP monograph]

Common Name

English

1,3-Benzenedicarboxamide, N,N?-bis[2-hydroxy-1-(hydroxymethyl)ethyl]-5-[(2-hydroxy-1-oxopropyl)amino]-2,4,6-triiodo-, (S)-

Systematic Name

English

Isovue

Brand Name

English

Iopamidol [INN]

Common Name

English

SQ13,396

Code

English

Iopamidol [EP impurity]

Common Name

English

Iopamidol [WHO-DD]

Common Name

English

1,3-Benzenedicarboxamide, N1,N3-bis[2-hydroxy-1-(hydroxymethyl)ethyl]-5-[[(2S)-2-hydroxy-1-oxopropyl]amino]-2,4,6-triiodo-

Systematic Name

English

Iopamidol [MI]

Common Name

English

Iopamidol [JAN]

Common Name

English

Iopamidol [MART.]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C28500